A Study of Saxagliptin in subjects with Type 2 diabetes who have inadequate blood sugar control with sulfonylureas

Study identifier:CV181-040

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Glyburide in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control with Glyburide Alone

Medical condition

diabetes

Phase

Phase 3

Healthy volunteers

No

Study drug

Saxagliptin, Glyburide, Placebo, Metformin

Sex

All

Actual Enrollment

768

Study type

Interventional

Age

18 Years - 77 Years

Date

Study Start Date: 01 Apr 2006
Primary Completion Date: 01 Sept 2007
Study Completion Date: 01 Sept 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria